Possibilities of polytropic therapy with thiotriazoline in patients with non-alcoholic steatohepatosis and cardiovascular risk factors. The results of the TRIGON-1 observation program

The article presents the results of the section of the multicenter Observation program TRIGON initiated by the Gastroenterology Scientifi c Society of Russia (GSSR). The aim of the TRIGON-1 study was to study the mechanisms of comorbidity formation in patients with non-alcoholic steatohepatosis and predictors of cardiovascular diseases (CVD) and the effect of multi-organ therapy on this. Over the course of two months, 30 patients with non-alcoholic steatohepatosis and predictors of CVD development who received thiotriazoline monotherapy were observed. It is shown that the formation of mechanisms of comorbidity of NAFLD and cardiovascular diseases occurs at the early stages of the development of these sufferings. Course monotherapy with drug multiple organ action - thiotriazoline in patients with NAFLD improves liver health and reduces the risk of CVD.

1. Oganov R. G., Denisov I. N., Simanenkov V. I., et al. Comorbidities in practice. Clinical guidelines. Cardiovascular Th erapy and Prevention. 2017;16(6):5–56. (In Russ.) https://doi.org/10.15829/1728–8800–2017–6–5–56

2. Lazebnik L. B., Konev Yu. V. Historical features and semantic difficulties of using the terms denoting multiplic-ity of diseases in one patient. Experimental and Clinical Gastroenterology. 2018;(6):4–9. (In Russ.)

3. Lazebnik L. B., Vertkin A. L., Konev Yu.V., Li E. D., Skotnikov A. S. Aging: a professional medical approach. (National leadership). Moscow. Eksmo Publ., 2014, 320 P.

4. Drapkina OM, Fadeeva M. Is atherosclerosis a liver disease? Reference book of a polyclinic doctor. 2013, No. 10, pp. 4–9.

5. Benedict M. et al. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol 2017 June 8; 9(16): 715–732.,

6. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1S):47–64. doi:10.1016/j.jhep.2014.12.012

7. Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol. 2017;9(16):715– 732. doi:10.4254/wjh.v9.i16.715

8. Simanenkov V. I., Sundukova Z. R., Solovyeva O. I. Complex therapy of irritable bowel syndrome. Consilium Medicum. 2017; 19 (8.2. Gastroenterology): 37–44. DOI: 10.26442/2075-1753_19.8.2.37-44

9. Byrne C.D., Targher G. Review. NAFLD: A multisystem disease. Journal of Hepatology. 2015:(62);47–64.

10. Jonathan M. Hazlehurst et al, Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016;65(8):1096–1108.

11. Esterbauer H., Gebicki J., Puhl H., Jurgens G. Th e role of lipid peroxidation and antioxidants in oxidative modifi cation of LDL. Free Radic. Biol. Med. 1992, no. 13, pp. 341–390.

12. Baraboy V. A., Sutkova D. A. Oxidative-antioxidant home o s t a si s i n he a lt h a nd d i s e a s e . К ie v. Chernobylinterinform Publ., 1997. Ch. 1, 2.

13. Kazimirko V. K., Maltsev V. I. Th e antioxidant system and its functioning in the human body. (available on line) http: www.healthua.com/2004

14. Belenichev I. F., Mazur I. A., Voloshin N. A. et al. Th e mechanism of anti-ischemic and antioxidant action of thiotriazoline. News of Medicine and Pharmacy. 2007;2 (206).

15. Beregovaya E. G. Infl uence on the cation-transport functions of biomembranes as the basis for the antiarrhythmic action of thiotriazoline. Actual nutrition of pharma-ceutical and medical science and practice. Zb. sciences. Art. Zaporizhya. 2002. Vol. 8, pp. 49–52.

16. Vizir A. D., Vizir V. A., Dunaev V. V., Mazur I. A. Th iotriazolin – creation, mechanism of action, achievements and prospects of application in medicine. Relevant nutrition of pharmaceutical and medical science and practice: Zb. sciences. Art. -Zaporizhya. 2002, Vol. 8, pp. 3–11.

17. Vizir A. D., Dunaev V. V., Mazur I. A. et al. Th iotriazolin – Zaporozhye: NPO Pharmatron. 1996, 27P.

18. Babadzhanyan EI. Th e use of thiotriazoline in chronic hepatitis. Ross. zhurn. gastroenterol., hepatol., coloproctol. 1995;5(3):12–13.

19. Belenichev I. F., Mazur I. A., Kovalenko S. I. Some as-pects of the anti-ischemic action of thiotriazoline in conditions of experimental cerebrovascular accident. Relevant nutrition of pharmaceutical and medical sci-ence and practice: Zb. sciences. Art. -Zaporizhya. 2002. Vol. 8, pp. 43–48.

20. Dunaev V. V., Belay I. M., Mazur I. A., Tishkin V. S. Evaluation of the pharmacodynamic eff ects of thiotri-azoline in hyperlipidemia. Relevant nutrition of pharma-ceutical and medical science and practice: Zb. sciences. Art. - Zaporizhzhya, 2002, Vip. 8, pp. 70–73.

21. Dunaev V. V., Belenichev I. F., Mazur I. A., Stets V. R. Pharmaco-biochemical aspects of the anti-ischemic action of the drug thiotriazoline under experimental conditions. Relevant nutrition of pharmaceutical and medical science and practice: Zb. sciences. Art. -Zaporizhya, 2002. Vip. 8, pp. 73–81.

22. Mazur I. A., Voloshin N. A., Chekman I. S. et al. Th iotriazoline: pharmacological aspects and clinical applications. Zaporizhzhia. 2005, 156 p.

23. Lazebnik L. B., Radchenko V. G., Golovanova E. V., et al. Non-alcoholic fatty liver disease: clinic, diagnostics, treatment (Recommendations for therapists, 2nd edition). Experimental and Clinical Gastroenterology. 2017;(2):22–37. (In Russ.)

24. Golovanova E. V. THE Pathogenetic approaches to the chronic liver diseases treatment. Experimental and Clinical Gastroenterology. 2016;(5):65–73. (In Russ.)

25. Bakulin I. G., Medvedev Yu. V. Assessment of the liver functional reserve in cirrhosis using the 13C-metacetin breath test (literature review and clinical observations). Annals of Surgical Hepatology, 2017;22(1):19–24.